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Summary The serum levels of CA 19-9 and carcinoembryonic antigen (CEA) were determined in 37 patients
with benign colorectal diseases and in 111 patients with newly discovered colorectal carcinomas or clinically
verified relapses. In cancer patients, the CA 19-9 level ranged from normal (0-37Uml-1) to 77,500Uml-P
whereas all samples but one from patients with benign colorectal diseases had a normal value. CA 19-9 was
increased in 46% and 45% of patients with an advanced (Dukes C or D) carcinoma or a verified recidive,
respectively. Only one out of 26 patients (4%) with a localized (Dukes A or B) carcinoma displayed an
elevated CA 19-9 level (>37Um.1-1). No clear correlation was found between the CA 19-9 and CEA levels.
The sensitivity of the CA 19-9 test (36%) was poorer than that of the CEA assay (69%), but the new test was
markedly more specific (97% vs 70%) than the CEA assay.
Carcinoembryonic antigen (CEA) was first
considered as a specific marker for colonic cancer
(Thomson et al., 1969), but further studies on this
antigen showed elevated levels in a large proportion
of patients with various malignant and benign
diseases (Zamcheck et al., 1972). The present status
of CEA in the diagnosis and follow-up of
malignomas clearly indiaFtes that the CEA
determination is a poor screening test for malignant
diseases. Serial CEA monitoring, however, gives
valuable information in the detection of residual or
recurrent cancer (Cooper et al., 1979; Goldenberg,
1979).
The CA 19-9 test is a new radioimmunoassay for
the measurement of a carbohydrate determinant
(sialylated lacto-N-Fucopentaose II) of a circulating
antigen (Del Villano et al., 1983). The assay
employs a monoclonal antibody originally raised
against a human colon carcinoma cell line (SW
1116) (Koprowski et al., 1979). Elevated CA 19-9
levels have been found in the serum of patients with
various gastro-intestinal carcinomas (Del Villano et
al., 1983; Koprowski et al., 1981) and the results of
Sears et al. (1982) indicate that the CA 19-9 antigen
is a new marker which can help in the diagnosis
and monitoring ofcolorectal carcinomas.
In this investigation, we have studied CA 19-9
and CEA levels in the serum of patients with a
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newly discovered, still untreated colorectal
carcinoma and in operated patients with residual
tumour or a clinically confirmed relapse. The main
emphasis has been focused on the comparison of
CA 19-9 and CEA values.
Materials and methods
Patients
A total of 111 patients with a histologically verified
colorectal carcinoma and 37 patients with benign
colorectal disease were included in this study. The
benign diseases consisted of colorectal polyposis (14
patients), benign adenoma (8), diverticulosis (6),
ulcerative colitis (8) and Crohns disease (1). The
cancer group included 71 patients with a newly
discovered cancer and 40 patients with an
antecedent operation and with a clinically verified
recurrence. Three of the newly discovered
carcinomas were stage A according to Dukes
classification, 23 were Dukes B, 17 were Dukes C
and 28 were Dukes D. Serum samples from patients
with a newly discovered carcinoma were taken
shortly before the operation and from patients with
an antecedent operation at the time of verification
of the relapse. Operated carcinoma patients without
any signs of relapse were not included in the study.
Assays
Serum CEA was determined by a
radioimmunoassay as described (Rutanen et al.,
C) The Macmillan Press Ltd., 1984136 P. KUUSELA et al.
1978). The CEA antiserum was purchased from
Dako a/s (Copenhagen, Denmark). A cut-off level
of 2.5ngml- was used for the CEA assay. The
values in our CEA test showed good correlation
(r2=0.9997) with the values obtained by Abbot-
CEA-RIA Diagnostic Kit (Abbot, Wiesbahn,
Germany) as tested with 100 serum samples
containing CEA from normal to 60,500ngml -1.
The CA 19-9 antigen was quantitated by a
commercially available solid phase
radioimmunoassay (Centocor, Melvern, PA, USA).
Employing a cut-off value of 37Uml-1, 0.6% of
normal blood bank donors have a higher
concentration (Del Villano et al., 1983).
Serum samples were stored at -20°C from 1-18
months before the CA 19-9 assay.
Results
The CA 19-9 antigen levels
The CA 19-9 level was normal (0-37Uml1) in all
but one of the 37 patients with a benign colorectal
disease (Figure 1). In patients with a newly
discovered colorectal cancer or a clinically verified
relapse the CA 19-9 value ranged from normal to
77,500 Uml- I (Figure 1). Elevated levels were
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clearly associated with advanced cancers. Only one
of the 26 patients with a localized carcinoma
(Dukes A or B) had an increased CA 19-9
concentration whereas a pathological CA 19-9
value was recorded in 47% of patients with a
Dukes C or D tumour. Elevated CA 19-9 levels
were detected in 45% of samples from operated
patients with verified recurrence (Figure 1).
Comparison ofCEA and CA 19-9 levels
No correlation between CEA and CA 19-9 levels
was found (r2=0.0269), as summarized in Table I
and Figure 2. In benign diseases, CEA was elevated
above the normal range (>2.5ngml-1) in 30% of
the patients while an elevated CA 19-9 value was
found in only 1/37 patients.
Eight patients (31%) with a localized carcinoma
had an elevated CEA level. However, none of the
Dukes A or B patients showed simultaneous
elevation of CEA and CA 19-9 (Table I). Both
markers were, on the other hand, elevated in 42%
of patients with a more advanced cancer (Dukes C
or D). In this group, a pathological CEA value
with a normal CA 19-9 concentration was found in
40% of the patients while the opposite was true in
only 2/45 patients (4%). The CEA level was normal
in 8 patients (20%) with an antecedent operation
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Figure 1 CA 19-9 antigen levels in patients with newly discovered colorectal carcinomas, in patients with
residual colorectal tumours or in clinically verified relapse and in patients with benign colorectal diseases. The
Dukes staging has been indicated as A, B, C and D.
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Table I Combinations of test finding in patients with colorectal carcinomas and
with benign colorectal diseases
Assayfinding
CEA- CEA- CEA +b CEA +
No. patients CA 19-9- CA J9_9+a CA 19-9- CA 19-9+
Benign 37 26 0 10 1
Dukes A or B 26 17 1 8 0
Dukes C or D 45 6 2 18 19
Relapses 40 7 1 15 17
Total 148 56 4 51 37
aCA 19-9+:>37Uml-
bCEA+: >2.5ngml-
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Figure 2 Correlation of CEA and CA 19-9. (0) patients with benign colorectal diseases, (0) patients with
newly discovered colorectal carcinomas or in clinically verified relapse.
and in clinically verified relapse. One of these
patients had a slightly elevated CA 19-9 value
(50Uml-1) (Table I). In operated patients with a
slightly (2,5-l0ngml-1) or clearly (>10ngml-1)
elevated CEA level, a pathological CA 19-9
concentration was found in 36% and in 50% of the
cases, respectively (Figure 1).
Assay parameters
Assay parameters were determined as shown in
Table II. Sensitivity of the CEA test was 69%, for
the CA 19-9 assay 36% and for the combination of
both determinations 73%. The best specificity was
obtained by the CA 19-9 quantitation (97%)
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Table H Assay parameters for the CEA test, for the CA
19-9 assay and for the combination of the tests
Assayfinding
CEA+and/or
Assay parameter CEA+a CA 19-9+b CA 19-9+
Sensitivityc 69 36 73
Specificitya 70 97 70
Predictive value' 88 98 88
aCEA+:>2.5ngml-l
bCA 19-9+:>37Umn-1
CSensitivity =TP/(TP+FN)
dSpecificity =TN/(TN+FP)
ePredictive value =TP/(TP+FP)
TP: true positive; FN: false negative; TN: true negative
and FP: false positive.
whereas specificities for the CEA determination and
for the combined tests were both 70%. The
predictive value for the CEA assay, for the CA 19-9
test and for the combined quantitation were 88%,
98% and 88%, respectively.
Discussion
The CEA measurement is a poor screening test for
colorectal cancer because high CEA values are
mainly found in patients with advanced cancer and,
on the other hand, benign gastro-intestinal diseases
are often associated with increased serum CEA
concentration (Zamcheck et al., 1972; Cooper et al.,
1979; Goldenberg, 1979). Our results indicate that
the sensitivity of the CA 19-9 assay is even lower
than that of the CEA measurement. Only 4% of
patients with a localized carcinoma had an elevated
CA 19-9 level and in patients with regional lymph
node metastases (Dukes C) the percentage was 35%
. These values are in accordance with the results of
Del Villano et al. (1983) who found elevated CA
19-9 values in 46% of patients with advanced
carcinomas and in 8% of patients with localized
tumours. The sensitivity of the CA 19-9 test could,
of course, be increased by lowering the cut-off level.
This would, however, decrease the specificity and
not significantly increase the detection of small
localized tumours, as can be seen in Figure 1.
Using a cut-off level of 37Uml-1, the specificity
(97%) and predictive value (98%) of the CA 19-9
assay were far better than those of the CEA test.
We found a slightly elevated CA 19-9 level in only
one patient with colonic pQlyposis whereas elevated
CEA values were found in 30% of the patients with
benign diseases. This finding is in good agreement
with the observation that CEA can be found in the
normal colorectal mucosa or in benign tumours
(Martin & Martin, 1972; Fritsche & Mach, 1977)
whereas Atkinson et al. (1982) failed to
demonstrate histochemically any CA 19-9 antigen
in the normal colon tissue. The expression of the
CA 19-9 antigen is, however, not specific for colon
cancer. Patients with hepatopathies combined with
elevated serum bilirubin levels can have increased
CA 19-9 concentrations (Jalanko et al. In press).
Elevated serum antigen levels can be found in
patients with various gastro-intestinal cancers such
as pancreatic, biliary tract and gastric carcinomas,
and also in some patients with benign upper gastro-
intestinal diseases (Del Villano et al., 1983). The
CA 19-9 is also found histochemically in
corresponding normal and malignant tissues
(Atkinson et al., 1982).
Sears et al. (1982) have previously performed a
longitudinal follow-up study of patients who had
their primary colorectal cancer surgically removed.
The cancer recurred in 10 of their patients and in 8
of these the serum CA 19-9 assay predicted the
recurrence 3-18 months prior to the development of
any clinical or laboratory sign. We studied CA 19-9
levels in 40 patients with a recurrent colorectal
cancer and found elevated CA 19-9 values in 45%
of them. The difference in the percentages of
elevated CA 19-9 levels between our patients and
those of Sears et al. (80%) may be due to the fact
that 9/10 patients in their series had increased CA
19-9 concentration already preoperatively whereas
our patients represented a random population with
regard to CA 19-9 values. No clear-cut correlation
was observed between CA 19-9 and CEA levels.
Because of the poor sensitivity neither of these
markers are optimal for screening of colorectal
carcinomas. In order to exclude minor CEA
variations not due to tumours the CEA
concentration 5ngml-1 has been accepted in many
laboratories as the cut-off point for the CEA
determination. In our data, this cut-off level results
only in minor changes in the assay parameters for
the CEA test and, consequently, has no effect on
the comparison of the CEA and CA 19-9
determinations. The differential expression of the
CA 19-9 antigen and the high predictive value for
the CA 19-9 assay (98%), however, suggest that
monitoring of CA 19-9 levels may give additional
information to that obtained by the CEA
determination. In this sense, the CA 19-9 antigen
can be a useful additional marker in the diagnosis
and follow-up of colorectal cancers.SERUM CA 19-9 AND CEA IN COLORECTAL DISEASE 139
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